Treatment with either Lip-BBR or Vild significantly upregulated the Beclin-1 and LC3-II immunoexpression in the T2DM-Lip-BBR and T2DM-Vild groups compared to the T2DM. The gene discussed is BECN1; the disease is type 2 diabetes mellitus.